Skip to main content

Harpoon Therapeutics, Inc.

HARPDelisted Mar 11, 2024
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001708493

Harpoon Therapeutics, Inc. was delisted on Mar 11, 2024; its insiders filed their last Form 4 on Mar 11, 2024; 41 institutions reported holding it in 13F filings for Q4 2023, worth $175.5M in total; no superinvestor held it.

Holders of 5% or more of HARP

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Harpoon Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.

No holder currently reports owning 5% or more of Harpoon Therapeutics, Inc. on Schedule 13D or 13G.

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

11 Schedule 13D and 13G filings on Harpoon Therapeutics, Inc., newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on HARP
Filed (ET)FilerFormStakeChangeEvent dateFiling
Feb 14, 2022Logos Global Management LP13G/AOld format–––SEC
Feb 11, 2022New Leaf Ventures III, L.P.13G/AOld format–––SEC
Feb 11, 2022OrbiMed Advisors LLC13G/AOld format–––SEC
Feb 4, 20224:12 PM ETBlackRock Inc.13GOld format–––SEC
Dec 27, 2021Logos Global Management LP13GOld format–New–SEC
Jul 16, 2021Arix Bioscience plc13D/AOld format–––SEC
May 6, 2021MPM BioVentures 2014, L.P.13D/AOld format–––SEC
Feb 16, 2021MPM BioVentures 2014, L.P.13D/AOld format–––SEC
Feb 12, 2021OrbiMed Advisors LLC13G/AOld format–––SEC
Feb 10, 20213:04 PM ETBlackRock Inc.13G/AOld format–––SEC
Feb 2, 20213:13 PM ETBlackRock Inc.13GOld format–New–SEC
Jan 12, 2021Arix Bioscience plc13D/AOld format–––SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell Harpoon Therapeutics, Inc. shares.

No Form 144 notices for Harpoon Therapeutics, Inc. are on file.